Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer

Incorporating dual human epidermal growth factor receptor 2 (HER2) blockade into neoadjuvant systemic therapy (NST) led to higher response in patients with HER2‐positive breast cancer. However, axillary response to treatment regimens, including single or dual HER2 blockade, in patients with clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Chihwan, Ahn, Sung Gwe, Kim, Dooreh, Lee, Janghee, Park, Soeun, Bae, Soong June, Kim, Jee Ye, Park, Hyung Seok, Park, Seho, Kim, Seung Il, Park, Byeong‐Woo, Jeong, Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457167/
https://www.ncbi.nlm.nih.gov/pubmed/34213778
http://dx.doi.org/10.1002/ijc.33726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457167/
https://www.ncbi.nlm.nih.gov/pubmed/34213778
http://dx.doi.org/10.1002/ijc.33726

Ejemplares similares